Rihito Kanamaru

633 total citations
26 papers, 461 citations indexed

About

Rihito Kanamaru is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Rihito Kanamaru has authored 26 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 6 papers in Surgery. Recurrent topics in Rihito Kanamaru's work include Gastric Cancer Management and Outcomes (8 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Rihito Kanamaru is often cited by papers focused on Gastric Cancer Management and Outcomes (8 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Rihito Kanamaru collaborates with scholars based in Japan and United States. Rihito Kanamaru's co-authors include Alan Kawarai Lefor, Naoki Hirabayashi, Yuh Sakata, M Kurihara, T Taguchi, Naohiro Sata, Joji Kitayama, Hideyuki Ohzawa, Hideyo Miyato and Yoshinori Hosoya and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Scientific Reports.

In The Last Decade

Rihito Kanamaru

26 papers receiving 449 citations

Peers

Rihito Kanamaru
Comparison fields: 5 of 60
  • Pulmonary and Respiratory Medicine 216
  • Oncology 192
  • Immunology 119
  • Surgery 104
  • Gastroenterology 72
Replace Futoshi Kawamata with:
Futoshi Kawamata Japan
Elizabeth Bird‐Lieberman United Kingdom
Masayuki Shinkai Japan
Tetsuya Takahara Japan
Masaki Ohashi Japan
Lin Ding China
Shozo Togawa Japan
Fumito Tamura Japan
Yohei Ozawa Japan
Raffaella Magris Italy
Futoshi Kawamata Japan View profile →
Citations per field, relative to Rihito Kanamaru
Rihito Kanamaru · 1×
Citations per year, relative to Rihito Kanamaru
Rihito Kanamaru · 1×

Countries citing papers authored by Rihito Kanamaru

Since Specialization
Citations

This map shows the geographic impact of Rihito Kanamaru's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rihito Kanamaru with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rihito Kanamaru more than expected).

Fields of papers citing papers by Rihito Kanamaru

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rihito Kanamaru. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rihito Kanamaru. The network helps show where Rihito Kanamaru may publish in the future.

Co-authorship network of co-authors of Rihito Kanamaru

This figure shows the co-authorship network connecting the top 25 collaborators of Rihito Kanamaru. A scholar is included among the top collaborators of Rihito Kanamaru based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rihito Kanamaru. Rihito Kanamaru is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1 1
2 4
3 8
4 26
5 19
6 6
7 2
8 9
9 26
10 3
11 1
12 63
13 25
14 1
15
[A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)].
68
16
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)].
74
17
[p53 mutation does not determine prognosis in non-Hodgkin's lymphoma].
1
18
[Genetic alterations of human colorectal cancer].
1
19
[Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group].
8
20
[Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].
2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026